降主动脉胸段动脉瘤腔内修复术:GREAT注册研究中期的报告
本研究基于Gore全球腔内主动脉治疗注册(GREAT)的多中心前瞻性观察队列,评估2010年8月至2016年10月期间接受GORE胸主动脉装置治疗降主动脉胸段动脉瘤(DTAA)患者的短中期结局。
要点
- TEVAR治疗DTAA技术成功率高,围手术期死亡和即刻中转开放手术罕见。
- 30天死亡率和神经系统事件发生率均为1.3%,再干预率为4.5%。
- 5年无主动脉相关死亡率为92.2%,无TEVAR相关再干预率为87.2%。
核心结论
- 使用GORE胸主动脉装置行TEVAR治疗DTAA与低装置相关再干预率相关,并在长达5年随访中有效预防主动脉相关死亡。
主要发现
- 30天窗口内死亡4例(1.3%),神经系统事件4例(1.3%)(短暂性脑缺血发作/卒中3例,截瘫1例),再干预率4.5%(14例)。
- 估计生存率6个月为95.6%(95%CI 92.6-97.4),1年为92.7%(95%CI 89.1-95.2),5年为57.3%(95%CI 48.5-65.1)。
- 无主动脉相关死亡率6个月和1年均为98.3%(95%CI 96.1-99.3),5年为92.2%(95%CI 83.4-96.4)。
- 5年无TEVAR相关再干预率为87.2%(95%CI 81.2-91.4)。
临床怎么用
- 对于解剖条件合适的降主动脉胸段动脉瘤患者,TEVAR是一种围手术期风险低、中期疗效确切的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to evaluate the short- to mid-term outcomes of descending thoracic aortic aneurysm (DTAA) repair from the Gore Global Registry for Endovascular Aortic Treatment (GREAT). METHODS: This is a multicentre sponsored prospective observational cohort registry. The study population comprised those treated for DTAA receiving GORE thoracic aortic devices for DTAA repair between August 2010 and October 2016. Major primary outcomes were early and late survival, freedom from aorta-related mortality and freedom from aorta-related reintervention. RESULTS: There were 180 (58.1%) males and 130 (41.9%) females: the mean age was 70 ± 11 years (range 18-92). The median maximum DTAA diameter was 60 mm (interquartile range 54-68.8). Technical success was achieved in all patients. Operative mortality, as well as immediate conversion to open repair, was never observed. At the 30-day window, mortality occurred in 4 (1.3%) patients, neurological events occurred in 4 (1.3%) patients (transient ischaemic attacks/stroke n = 3, paraplegia n = 1) and the reintervention rate was 4.5% (n = 14). Estimated survival was 95.6% [95% confidence interval (CI) 92.6-97.4] at 6 months, 92.7% (95% CI 89.1-95.2) at 1 year and 57.3% (95% CI 48.5-65.1) at 5 years. Freedom from aorta-related mortality was 98.3% (95% CI 96.1-99.3) at 6 months, 98.3% (95% CI 96.1-99.3) at 1 year and 92.2% (95% CI 83.4-96.4) at 5 years. Freedom from thoracic endovascular aortic repair (TEVAR)-related reintervention at 5 years was 87.2% (95% CI 81.2-91.4). CONCLUSIONS: TEVAR for DTAAs using GORE thoracic aortic devices is associated with a low rate of device-related reinterventions and is effective at preventing aorta-related mortality for up to 5 years of follow-up. CLINICAL REGISTRATION NUMBER: NCT number: NCT01658787. SUBJECT COLLECTION: 161, 164.
引用
- Grassi V, Trimarchi S, Weaver F, et al. Endovascular repair of descending thoracic aortic aneurysms-a mid-term report from the Global Registry for Endovascular Aortic Treatment (GREAT). Eur J Cardiothorac Surg. 2022. PMID: 34392333. doi:10.1093/ejcts/ezab366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。